Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials, Journal of Experimental & Clinical Cancer Research, May 2011, Springer Science + Business Media,
DOI: 10.1186/1756-9966-30-54.
You can read the full text:

Read

Contributors

The following have contributed to this page